Sage Therapeutics, Inc.

Pliant Therapeutics, Inc.

Jian Wang

Bret Berner

Paul Steven Watson

John Gregory Reid

Stephen Jay Kanes

James J Doherty

Katerina Leftheris

Dalian Zhao

Qi Gao

Jacob Cha

This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid

Provided herein are integrin inhibitors, compositions thereof, and methods of their uses. Crystalline forms of salts of the inhibitors are also described, along with methods of preparing the crystalline forms. X-ray powder diffraction data, thermogravimetric analysis, and differential scanning calorimetry data are provided for the crystalline forms. The integrin inhibitors are useful for treatment of, inter alia, fibrotic diseases.

Integrin inhibitor and uses thereof

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof. 

Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid

Growing community of inventors

Branchburg, NJ, United States of America

Jian Wang